- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04924192
A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer
September 18, 2021 updated by: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
This is an open, multi-cohort, exploratory phase II study on the safety and efficacy of TQB3616 combined with Anlotinib hydrochloride capsules or standard chemotherapy in the treatment of advanced lung cancer.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
126
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yongsheng Li, Doctor
- Phone Number: 18980602258
- Email: wangys@wchscu.cn
Study Locations
-
-
Chongqing
-
Chongqing, Chongqing, China, 400000
- Recruiting
- Chongqing University Cancer Hospital
-
Contact:
- Jianghong Wang, Master
- Phone Number: 13983841209
- Email: wjhwin16@163.com
-
-
Gansu
-
Lanzhou, Gansu, China, 730000
- Recruiting
- The First Hospital of Lanzhou University
-
Contact:
- Hongmei Yue, Master
- Phone Number: 13893265368
- Email: 13893289062@139.com
-
-
Guizhou
-
Guiyang, Guizhou, China, 550002
- Recruiting
- Guizhou Provincial People's Hospital
-
Contact:
- Yu Zhang, Doctor
- Phone Number: 18885146684
- Email: 248634489@qq.com
-
-
Shanxi
-
Xi'an, Shanxi, China, 710038
- Recruiting
- The Second Affiliated Hospital of PLA Air Force Military Medical University
-
-
Sichuan
-
Chengdou, Sichuan, China, 610041
- Recruiting
- West China Hospital of Sichuan University
-
Contact:
- Yongsheng Li, Doctor
- Phone Number: 18980602258
- Email: wangys@wchscu.cn
-
Chengdu, Sichuan, China
- Recruiting
- Sichuan Cancer Hospital
-
Contact:
- Wenxiu Yao, Doctor
- Phone Number: 18908178836
- Email: ywxhlx@sina.com
-
-
Yunnan
-
Kunming, Yunnan, China, 650011
- Recruiting
- Yunnan Cancer Hospital
-
Contact:
- Runxiang Yang, Doctor
- Phone Number: 13888876721
- Email: 13888876721@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects with pathologically proven small cell lung cancer(SCLC) or/and locally advanced ( Stage ⅢB/ ⅢC), metastatic or recurrent (Stage IV) non small cell lung cancer(NSCLC).
- Cohort 1: Subjects with SCLC who had previously received at least one chemotherapy containing platinum or got disease progression during chemoradiotherapy or after the last treatment.
- Cohort 2: Subjects with locally advanced, metastatic/relapsed NSCLC who had previously received only one PD (L) 1 inhibitor alone or in combination with platinum-based chemotherapy.
- Subjects with measurable lesions as defined by RECIST 1.1.
- Aged ≥ 18 years ; Eastern Cooperative Oncology Group (ECOG) score: 0 ~ 1; Expected survival ≥ 3 months.
- Laboratory indicators meet the requirements.
- Non-pregnant or non-breastfeeding women; Negative pregnancy subjects.
- Subjects voluntarily joined the study and signed the informed consent form.
Exclusion Criteria:
- Subjects who received prior therapy with anlotinib hydrochloride capsules.
- Cohort 2: Subjects with epidermal growth factor receptor(EGFR) mutation and anaplastic lymphoma kinase(ALK) translocation.
- Subjects with central squamous cell carcinoma with a risk of hemoptysis.
- Subjects who have developed or is currently suffering from other malignancies within 5 years, with the exception of cured skin basal cell carcinoma and cervical carcinoma in situ.
- Subjects who have brain metastases with symptoms or control of symptoms for less than 2 months.
- Subjects with difficulty taking oral medication.
- Subjects with uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated drainage.
- Subjects with spinal cord compression who have failed to be cured or relieved by surgery and or radiotherapy.
- Subjects who have received chemotherapy, radiotherapy or other experimental anticancer therapy within 4 weeks prior to the first dose of the drug.
- Subjects who have not recovered to ≤ CTCAE Grade 1 (excluding alopecia) due to the adverse event of prior therapy.
- Subjects with significant surgery or significant traumatic injury within 28 days before randomization.
- Subjects with arterial/venous thrombosis within 6 months.
- Subjects with a history of psychotropic substance abuse who cannot be withdrawn or have mental disorders.
- Subjects with any severe and/or uncontrolled disease.
- Subjects whose large vessels are involved by tumor from imaging (CT or MRI).
- Subjects who have hemoptysis and maximum daily hemoptysis ≥ 2.5ml within 1 month before the first dose.
Subjects with other factors that might cause the study to be terminated halfway per the judgement of the investigator.
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: TQB3616 capsules+Anlotinib hydrochloride capsules
TQB3616 capsules 120/150/180mg orally on an empty stomach, once a day for 21 consective days as a treatment cycle;Anlotinib hydrochloride capsules 12mg, once a day for 2 consecutive weeks and stop for 1 week.
|
A CDK4/6 kinase inhibitor
A multi-target receptor tyrosine kinase inhibitor
|
EXPERIMENTAL: TQB3616 capsules +Irinotecan Hydrochloride for Injection
TQB3616 capsules 120/150/180mg orally on an empty stomach, once a day for 28 consecutive days as a treatment cycle.
Irinotecan Hydrochloride Injection 100 mg/m2 intravenous infusion on D1、D8 and D15, a total of 4-6 cycles.
|
A CDK4/6 kinase inhibitor
An inhibitor of DNA topoisomerase Ⅰ
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate (ORR)
Time Frame: up to 96 weeks
|
Percentage of participants achieving complete response (CR) and partial response (PR).
|
up to 96 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease control rate(DCR)
Time Frame: up to 96 weeks
|
Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD).
|
up to 96 weeks
|
Progression-free survival (PFS)
Time Frame: up to 96 weeks
|
PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.
|
up to 96 weeks
|
Duration of Response (DOR)
Time Frame: up to 120 weeks
|
The time when the participants first achieved CR or PR to disease progression or death from any cause.
|
up to 120 weeks
|
6-month progression-free survival rate
Time Frame: up to 96 weeks
|
PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.
|
up to 96 weeks
|
6-month and 12-month overall survival rate
Time Frame: up to 96 weeks
|
OS defined as the time from randomization to death from any cause.
Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.
|
up to 96 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
August 18, 2021
Primary Completion (ANTICIPATED)
May 23, 2023
Study Completion (ANTICIPATED)
December 30, 2023
Study Registration Dates
First Submitted
June 10, 2021
First Submitted That Met QC Criteria
June 10, 2021
First Posted (ACTUAL)
June 11, 2021
Study Record Updates
Last Update Posted (ACTUAL)
September 21, 2021
Last Update Submitted That Met QC Criteria
September 18, 2021
Last Verified
September 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TQB3616-ALTN-II-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Lung Carcinoma
-
Mayo ClinicRecruitingMultiple Myeloma | Myelodysplastic Syndrome | Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | Hematopoietic and Lymphoid System Neoplasm | Advanced Lung Carcinoma | Advanced Prostate Carcinoma | Advanced Glioblastoma | Advanced Gastric Carcinoma | Advanced Breast Carcinoma | Advanced Colorectal... and other conditionsUnited States
-
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.RecruitingAdvanced Solid Tumor | Advanced Gastric Carcinoma | Advanced Cholangiocarcinoma | Advanced Lung CancerChina
-
Polaris GroupTerminatedGlioma | Hepatocellular Carcinoma | Uveal Melanoma | Sarcomatoid Carcinoma | Pleural Mesothelioma Malignant Advanced | Peritoneal Mesothelioma Malignant Advanced | Non-squamous Non-small Cell Lung CarcinomaUnited States, United Kingdom
-
Assistance Publique - Hôpitaux de ParisTerminatedAdvanced Head and Neck Carcinoma | Advanced Non-small Cell Lung CarcinomaFrance
-
Mayo ClinicNot yet recruitingMetastatic Lung Non-Small Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Resectable Lung Non-Small Cell Carcinoma | Metastatic Malignant Solid Neoplasm | Metastatic Bladder Urothelial Carcinoma | Metastatic Colorectal Carcinoma | Metastatic Triple-Negative Breast Carcinoma | Locally... and other conditionsUnited States
-
Shanghai Fosun Pharmaceutical Industrial Development...RecruitingAdvanced Solid Tumor | Advanced Cancer | Lung Cancer, Nonsmall CellChina
-
National Cancer Institute (NCI)RecruitingAdenocarcinoma | Advanced Non-Small Cell Lung Cancer | Squamous Cell Carcinoma | Advanced NSCLC | Adenosquamous CarcinomaUnited States
-
TakedaCompletedCarcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid TumorsSpain, Italy, Netherlands, France
-
Cancer Institute and Hospital, Chinese Academy...RecruitingAdvanced Lung CarcinomaChina
-
LianBio LLCRecruitingAdvanced Solid Tumor | Advanced or Metastatic Non-small Cell Lung CancerChina
Clinical Trials on TQB3616 capsules
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingHR-positive,HER2-negative in Advanced Breast CancerChina
-
Peking UniversityNot yet recruiting
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingDedifferentiated LiposarcomaChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.CompletedRecurrent/Metastatic Breast CancerChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruiting
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownAdvanced Breast Cancer
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingHR-positive, HER2-negative Advanced Breast CancerChina
-
Reata, a wholly owned subsidiary of BiogenAbbVie; Friedreich's Ataxia Research AllianceActive, not recruitingFriedreich AtaxiaUnited States, Australia, Austria, Italy, United Kingdom
-
Reata, a wholly owned subsidiary of BiogenAbbVieCompletedMItochondrial MyopathiesUnited States, Denmark
-
Reata, a wholly owned subsidiary of BiogenTerminatedConnective Tissue Disease-Associated Pulmonary Arterial HypertensionUnited States, Spain, Japan, Australia, United Kingdom, Canada, Germany, Belgium, Argentina, Israel, Mexico, Brazil, Czechia, Netherlands, Philippines